IL15 and acute lymphoblastic leukemia: Lastly, a Phase I study in T-ALL patients found that the administration of CD5-IL15/IL15sushi CAR led to a rapid reduction in the malignant T cell count within 4 weeks of infusion (43) (see section 4.1.2).